- Home
- PHT vs PRQR Comparison
PHT vs PRQR Comparison
Compare PHT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- PRQR
- Stock Information
- Founded
- PHT 2002
- PRQR 2012
- Country
- PHT United States
- PRQR Netherlands
- Employees
- PHT N/A
- PRQR N/A
- Industry
- PHT Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- PRQR Health Care
- Exchange
- PHT Nasdaq
- PRQR Nasdaq
- Market Cap
- PHT 244.7M
- PRQR 232.8M
- IPO Year
- PHT N/A
- PRQR 2014
- Fundamental
- Price
- PHT $8.34
- PRQR $2.08
- Analyst Decision
- PHT
- PRQR Strong Buy
- Analyst Count
- PHT 0
- PRQR 8
- Target Price
- PHT N/A
- PRQR $8.88
- AVG Volume (30 Days)
- PHT 85.5K
- PRQR 367.9K
- Earning Date
- PHT 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- PHT 8.76%
- PRQR N/A
- EPS Growth
- PHT N/A
- PRQR N/A
- EPS
- PHT 0.98
- PRQR N/A
- Revenue
- PHT N/A
- PRQR $20,129,184.00
- Revenue This Year
- PHT N/A
- PRQR N/A
- Revenue Next Year
- PHT N/A
- PRQR N/A
- P/E Ratio
- PHT $7.71
- PRQR N/A
- Revenue Growth
- PHT N/A
- PRQR 8.65
- 52 Week Low
- PHT $6.41
- PRQR $1.07
- 52 Week High
- PHT $7.60
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PHT 53.80
- PRQR 50.33
- Support Level
- PHT $8.20
- PRQR N/A
- Resistance Level
- PHT $8.34
- PRQR $2.50
- Average True Range (ATR)
- PHT 0.04
- PRQR 0.15
- MACD
- PHT -0.45
- PRQR -0.11
- Stochastic Oscillator
- PHT 99.58
- PRQR 83.20
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.